AR077405A1 - DERIVATIVES OF INDOL INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CANCER - Google Patents

DERIVATIVES OF INDOL INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CANCER

Info

Publication number
AR077405A1
AR077405A1 ARP100102473A ARP100102473A AR077405A1 AR 077405 A1 AR077405 A1 AR 077405A1 AR P100102473 A ARP100102473 A AR P100102473A AR P100102473 A ARP100102473 A AR P100102473A AR 077405 A1 AR077405 A1 AR 077405A1
Authority
AR
Argentina
Prior art keywords
alkyl
radicals
chosen
alkoxy
radical
Prior art date
Application number
ARP100102473A
Other languages
Spanish (es)
Inventor
Jean-Marie Ruxer
Patrick Mailliet
Herve Minoux
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR077405A1 publication Critical patent/AR077405A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Su uso como medicamentos para el tratamiento del cáncer. Y métodos para su preparacion e intermediarios para su síntesis. Reivindicacion 1: Productos de formula (1) en los que: R2 y R3 idénticos o diferentes representan H, CH3, CH2CH3, CF3; Het representa un heterociclo aromático o parcialmente insaturado - de tipo dihidro o tetrahidro - mono o bicíclico, de 5 a 11 eslabones, que contiene de 1 a 4 heteroátomos, elegidos entre N, O o S, sustituido opcionalmente con uno o varios radicales R1 o R'1 idénticos o diferentes, tales como se describen a continuacion; R se elige del grupo constituido por los restos del grupo de formulas (2); con R1 y/o R'1, idénticos o diferentes, elegidos del grupo constituido por H, halogeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, fenilalcoxi, alquiltio, carboxi libre o esterificado por un radical alquilo, carboxamida, CO-NH(alquilo), CON(alquilo)2, NH-CO-alquilo, sulfonamida, NH-SO2-alquilo, S(O)2-NH-alquilo, S(O2)-N(alquilo)2, estando todos los radicales alquilo, alcoxi y alquiltio ellos mismos sustituidos opcionalmente con uno o varios radicales idénticos o diferentes elegido(s) entre halogeno, hidroxi, alcoxi, amino, alquilamino y dialquilamino; W1, W2, W3 representan independientemente CH o N; X representa un átomo de oxígeno o de azufre o un radical NR4, C(O), S(O) o S(O)2; V representa un átomo de hidrogeno o un átomo de halogeno o un radical -O-R4 o un radical -NH-R4 en el que: R4 representa un átomo de hidrogeno o un radical alquilo C1-6, cicloalquilo C3-8 o heterocicloalquilo C3-10, mono o bicíclico; estando estos radicales alquilo, cicloalquilo y heterocicloalquilo sustituidos opcionalmente con uno o varios radicales idénticos o diferentes elegido(s) entre los radicales: -O-PO3H2; -O-PO3Na2; -O-SO3H2; -O-SO3Na2; -O-CH2-PO3H2; -O-CH2-PO3Na2; -O-CO-alanina; -O-CO-glicina; -O-CO-serina; -O-CO-lisina -O-CO-arginina; -O-CO-glicina-lisina; -O-CO-alanina-lisina; halogeno; hidroxi; mercapto; amino; carboxamida (CONH2); carboxi; heterocicloalquilo; cicloalquilo; heteroarilo; carboxi esterificado por un radical alquilo; -CO-NH(alquilo); -O-CO-alquilo; -NH-CO-alquilo; alquilo; alcoxi ; alquiltio; alquilamino; dialquilamino; en todos estos ultimos radicales, estando los radicales alquilo, alcoxi y alquiltio ellos mismos sustituidos opcionalmente con uno o varios radicales idénticos o diferentes elegidos entre los radicales hidroxi, mercapto, amino, alquilamino, dialquilamino, CO2-alquilo, NHCO2-alquilo y heterocicloalquilo; en todos estos radicales, estando los radicales cicloalquilo, heterocicloalquilo y heteroarilo ellos mismos sustituidos opcionalmente con uno o varios radicales idénticos o diferentes elegido(s) entre los radicales hidroxi, alquilo, alcoxi, CH2OH; amino, alquilamino, dialquilamino, CO2-alquilo o NHCO2-alquilo; estando dichos productos de formula (1) en todas las formas tautomeras e isomeras posibles, racémicas, enantiomeras y diastereoisomeras, así como sales de adicion con los ácidos minerales y orgánicos o con las bases minerales y orgánicas de los productos de formula (1), así como los profármacos de los productos de formula (1). Reivindicacion 14: Como productos industriales, los intermedios de síntesis de formulas (3), (4), (5) y (6) en los que los sustituyentes Het, R, R4, W1 y W2 tienen los significados indicados en una cualquiera de las reivindicaciones 1 a 6 y z, R2 y R3 tienen los significados indicados anteriormente.Its use as medicines for cancer treatment. And methods for its preparation and intermediaries for its synthesis. Claim 1: Products of formula (1) in which: identical and different R2 and R3 represent H, CH3, CH2CH3, CF3; Het represents an aromatic or partially unsaturated heterocycle - dihydro or tetrahydro - mono or bicyclic, with 5 to 11 links, containing 1 to 4 heteroatoms, chosen from N, O or S, optionally substituted with one or more radicals R1 or R'1 identical or different, as described below; R is chosen from the group consisting of the remains of the formula group (2); with R1 and / or R'1, identical or different, chosen from the group consisting of H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, free or esterified carboxy by an alkyl radical, carboxamide, CO-NH (alkyl), CON (alkyl) 2, NH-CO-alkyl, sulfonamide, NH-SO2-alkyl, S (O) 2-NH-alkyl, S (O2) -N (alkyl) 2, all alkyl, alkoxy and alkylthio radicals themselves being optionally substituted with one or more identical or different radicals chosen from halogen, hydroxy, alkoxy, amino, alkylamino and dialkylamino; W1, W2, W3 independently represent CH or N; X represents an oxygen or sulfur atom or a radical NR4, C (O), S (O) or S (O) 2; V represents a hydrogen atom or a halogen atom or a radical -O-R4 or a radical -NH-R4 in which: R4 represents a hydrogen atom or a C1-6 alkyl radical, C3-8 cycloalkyl or C3 heterocycloalkyl -10, mono or bicyclic; these alkyl, cycloalkyl and heterocycloalkyl radicals being optionally substituted with one or more identical or different radicals chosen from the radicals: -O-PO3H2; -O-PO3Na2; -O-SO3H2; -O-SO3Na2; -O-CH2-PO3H2; -O-CH2-PO3Na2; -O-CO-alanine; -O-CO-glycine; -O-CO-serine; -O-CO-lysine -O-CO-arginine; -O-CO-glycine-lysine; -O-CO-alanine-lysine; halogen; hydroxy; mercapto; Not me; carboxamide (CONH2); carboxy; heterocycloalkyl; cycloalkyl; heteroaryl; carboxy esterified by an alkyl radical; -CO-NH (alkyl); -O-CO-alkyl; -NH-CO-alkyl; I rent; alkoxy; alkylthio; alkylamino; dialkylamino; in all of these latter radicals, the alkyl, alkoxy and alkylthio radicals themselves being optionally substituted with one or more identical or different radicals chosen from among the hydroxy, mercapto, amino, alkylamino, dialkylamino, CO2-alkyl, NHCO2-alkyl and heterocycloalkyl radicals; in all these radicals, the cycloalkyl, heterocycloalkyl and heteroaryl radicals themselves being optionally substituted with one or several identical or different radicals chosen from the hydroxy, alkyl, alkoxy, CH2OH radicals; amino, alkylamino, dialkylamino, CO2-alkyl or NHCO2-alkyl; said products of formula (1) being in all possible tautomeric and isomeric, racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with the mineral and organic acids or with the mineral and organic bases of the products of formula (1), as well as the prodrugs of the products of formula (1). Claim 14: As industrial products, the synthesis intermediates of formulas (3), (4), (5) and (6) in which the substituents Het, R, R4, W1 and W2 have the meanings indicated in any one of claims 1 to 6 and z, R2 and R3 have the meanings indicated above.

ARP100102473A 2009-07-10 2010-07-08 DERIVATIVES OF INDOL INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CANCER AR077405A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0954805 2009-07-10

Publications (1)

Publication Number Publication Date
AR077405A1 true AR077405A1 (en) 2011-08-24

Family

ID=41615811

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102473A AR077405A1 (en) 2009-07-10 2010-07-08 DERIVATIVES OF INDOL INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CANCER

Country Status (2)

Country Link
AR (1) AR077405A1 (en)
WO (1) WO2011004132A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003754A (en) * 2022-04-28 2023-11-07 腾讯科技（深圳）有限公司 Pyrrolo [2,3-d ] pyrimidine or pyrazolo [3,4-d ] pyrimidine derivatives and uses thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2476087A1 (en) 1980-02-18 1981-08-21 Roussel Uclaf NOVEL OXIMES DERIVED FROM 3-ALKYLOXY OR 3-ALKYL-THIOMETHYL 7-AMINO THIAZOLYL ACETAMIDO CEPHALOSPORANIC ACID, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
CN100358883C (en) 1998-06-02 2008-01-02 中国科学院上海有机化学研究所 Five-membered aromatic heterocyclic compounds contg. beta-position trifluoromethyl group and synthesis thereof
FR2792316B1 (en) 1999-04-13 2001-06-22 Synthelabo 1-AMINOETHYLINDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
KR100850727B1 (en) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 Small molecule compositions for binding to hsp90
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp Hsp90-inhibiting zearalanol compounds and methods of producing and using same
EP1521625B1 (en) 2002-07-11 2009-03-11 GEA BGR Energy System India Ltd. A debris filter with a rotating debris extractor
US7037522B2 (en) 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
US7241754B2 (en) 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
WO2005000778A1 (en) 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Hsp90 FAMILY PROTEIN INHIBITORS
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
AU2004200774A1 (en) 2003-07-07 2005-01-27 Holyrood Exports Pty Ltd Padlock Protector
WO2005006322A1 (en) 2003-07-11 2005-01-20 Konica Minolta Opto, Inc. Optical pickup device, optical element used for optical pickup device, and method for producing optical element
JP4783731B2 (en) 2003-08-29 2011-09-28 ヴァーナリス（ケンブリッジ）リミテッド Pyrimidothiophene compound
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
DE10354133A1 (en) 2003-11-19 2005-06-23 Phoenix Ag conveyor belt
KR101154351B1 (en) 2003-12-23 2012-06-15 인피니티 디스커버리, 인코포레이티드 Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
WO2005072766A2 (en) 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
JP2005225787A (en) 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Hsp90 inhibitor
JP4254633B2 (en) 2004-06-28 2009-04-15 株式会社イトーキ Rotation control device for swivel chair
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
WO2006010595A1 (en) 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
AR050084A1 (en) 2004-07-27 2006-09-27 Novartis Ag BENCIMIDAZOLONE DERIVATIVES AS HSP90 INHIBITORS
KR101045324B1 (en) 2004-08-11 2011-06-30 한국생명공학연구원 Geldanamycin derivatives and the method for biosynthesis thereof
DE102004039280A1 (en) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-diphenyl-pyrazoles
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US7422759B2 (en) 2004-11-03 2008-09-09 K2 Concepts, Inc. Anti-microbial compositions and methods of making and using the same
MX2007005940A (en) * 2004-11-18 2007-06-19 Synta Pharmaceuticals Corp Triazole compounds that modulate hsp90 activity.
FR2880540B1 (en) 2005-01-13 2008-07-11 Aventis Pharma Sa USE OF PURINE DERIVATIVES AS INHIBITORS OF HSP90 PROTEIN
GB0501535D0 (en) 2005-01-25 2005-03-02 Vernalis R&D Ltd Pyrimidothiophene compounds
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
DE102005007304A1 (en) 2005-02-17 2006-08-24 Merck Patent Gmbh triazole derivatives
FR2882361A1 (en) 2005-02-22 2006-08-25 Aventis Pharma Sa New 3-aryl-1,2-benzisoxazole compounds are heat shock protein 90 inhibitors, useful to treat solid or liquid cancer, preferably cancers resistant to cytotoxic agents
KR20150029766A (en) 2005-02-25 2015-03-18 에사넥스, 인코포레이티드 Tetrahydroindolone and tetrahydroindazolone derivatives
WO2006090094A1 (en) 2005-02-28 2006-08-31 Vernalis R & D Ltd Pyrimidothiophene compounds for use as hsp90 inhibitors
JP5044730B2 (en) 2005-03-09 2012-10-10 日本化薬株式会社 Novel HSP90 inhibitor
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
JPWO2006100907A1 (en) 2005-03-22 2008-09-04 松下電器産業株式会社 Imaging device and portable wireless communication terminal
JP2008137894A (en) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd New acetylene derivative
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
FR2884252B1 (en) 2005-04-08 2007-05-18 Aventis Pharma Sa NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY
EP1877379B1 (en) 2005-04-13 2013-01-16 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
JP2008536867A (en) 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 2-Amino-quinazolin-5-one as an HSP90 inhibitor useful in treating proliferative diseases
JP2008540395A (en) 2005-05-03 2008-11-20 ファイザー・インク Amidoresorcinol compounds
FR2885904B1 (en) 2005-05-19 2007-07-06 Aventis Pharma Sa NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
DE102005022977A1 (en) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
FR2886038B1 (en) 2005-05-20 2008-02-01 Fasver Sa Sa ANTI-FALSIFY FLEXIBLE SAFETY ADHESIVE VIGNETTE, OFFICIAL DOCUMENT COMPRISING SUCH A THUMBNAIL AND A METHOD OF MANUFACTURING THE SAME
EP1893618A2 (en) 2005-05-25 2008-03-05 Nycomed GmbH Tetrahydropyridothiophenes for use in the treatment of cancer
EP1896484A2 (en) 2005-05-25 2008-03-12 Nycomed GmbH Tetrahydropyridothiophenes for use in the treatment of cancer
DE102005024245A1 (en) 2005-05-27 2006-11-30 Merck Patent Gmbh thienopyridines
BRPI0611601A2 (en) 2005-06-20 2010-09-21 Ash Access Technology Inc anticoagulant resident catheter
CN101213178A (en) 2005-06-29 2008-07-02 协和发酵工业株式会社 Benzenoid ansamycin derivative
DE102005037733A1 (en) 2005-08-10 2007-02-15 Merck Patent Gmbh adenine
WO2007022042A2 (en) 2005-08-11 2007-02-22 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2007021877A1 (en) 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي 2-Amino-7,8-Dihidro-6H-Pyrido(4,3-D)Pyrimidin-5-ones
US7745893B2 (en) 2005-10-17 2010-06-29 Northern Lights Semiconductor Corp. Magnetic transistor structure
US20070105862A1 (en) 2005-11-10 2007-05-10 Milan Bruncko Heat-shock protein binders
WO2007064926A2 (en) 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
WO2007074347A1 (en) 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents
EP2012791A4 (en) 2006-02-07 2010-09-22 Conforma Therapeutics Corp 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
ATE531718T1 (en) 2006-03-11 2011-11-15 Vernalis R&D Ltd PYRROLOPYRIMIDE DERIVATIVES USED AS HSP90 INHIBITORS
WO2007117466A2 (en) 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
KR20090021155A (en) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Pyrimidine derivatives as pi3k inhibitors
US20090142337A1 (en) 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
GB0609117D0 (en) 2006-05-09 2006-06-21 Biotica Tech Ltd Novel compounds
CA2651558A1 (en) 2006-05-09 2007-11-15 Biotica Technology Limited Novel compounds
WO2007134298A2 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
DE102006023337A1 (en) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazole derivatives II
DE102006023336A1 (en) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-diphenyl-pyrazoles II
AU2007267847B2 (en) 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
TW200806637A (en) 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
SI2035396T1 (en) 2006-05-25 2014-08-29 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2653327A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
WO2007139951A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
TWI490212B (en) 2006-05-25 2015-07-01 Synta Pharmaceuticals Corp Triazole compounds that modulate hsp90 activity
RU2568579C2 (en) 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Introduction of anti-coagulating system reg1
AR061185A1 (en) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS.
WO2008150302A1 (en) 2007-06-04 2008-12-11 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with radicicol and its derivatives
DE102006030479A1 (en) 2006-07-01 2008-03-20 Merck Patent Gmbh indazole
CN101588799B (en) 2006-08-11 2013-09-11 斯特拉斯堡大学 Macrocyclic compounds useful as inhibitors of kinases and hsp90
WO2008020024A1 (en) 2006-08-16 2008-02-21 4Sc Ag Ntetrahydropyridothiophene derivatives for the treatment of cancer
JP2010500396A (en) 2006-08-16 2010-01-07 ４エスツェー アクチェンゲゼルシャフト Tetrahydrobenzothiophene derivatives
AU2007284537B2 (en) 2006-08-17 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20080070930A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
US20080070918A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
US20080070933A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Purine, Pyrimidine, and Azaindole Derivatives
WO2008024977A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
KR101485199B1 (en) 2006-09-19 2015-01-22 다이이찌 산쿄 가부시키가이샤 Pyrazolopyrimidine derivative
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
CL2007002994A1 (en) 2006-10-19 2008-02-08 Wyeth Corp HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
FR2907453B1 (en) 2006-10-24 2008-12-26 Sanofi Aventis Sa NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
US20100280032A1 (en) 2006-10-26 2010-11-04 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008059368A2 (en) 2006-11-17 2008-05-22 Pfizer Products Inc. Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
PE20081506A1 (en) 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
KR100872664B1 (en) 2006-12-15 2008-12-10 현대자동차주식회사 Air conditioner compressor having friction member in cylinder
DE102007002715A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh triazole
RU2009132605A (en) 2007-02-01 2011-03-10 Астразенека Аб (Se) 5,6,7,8-TETRAGHYDROPERTERIDINE DERIVATIVES AS HSP90 INHIBITORS
US20100093696A1 (en) 2007-02-06 2010-04-15 Pfizer Inc. 2-amino pyrimidine compounds
CN101679319B (en) 2007-02-08 2014-07-09 辛塔医药品有限公司 Triazole compounds that modulate hsp90 activity
TW200904417A (en) 2007-02-20 2009-02-01 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
CL2008000629A1 (en) 2007-03-01 2008-08-29 Chugai Pharmaceutical Co Ltd MACROCICLICAL COMPOUNDS DERIVED FROM 6-ARIL-4-MERCAPTO- [1.3.5] TRIAZINA / [1.3] PIRIMIDIN-2-AMINA; PHARMACEUTICAL COMPOSITION, USEFUL IN THE TREATMENT OF CANCER.
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
WO2008112199A1 (en) 2007-03-12 2008-09-18 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase ii
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
EA019103B1 (en) 2007-03-20 2014-01-30 Кьюрис, Инк. Fused amino pyridine as hsp90 inhibitors
JP5529004B2 (en) 2007-03-27 2014-06-25 シンタ ファーマシューティカルズ コーポレーション Triazinone and diazinone derivatives useful as HSP90 inhibitors
US20080269193A1 (en) 2007-04-16 2008-10-30 Kenneth He Huang Tetrahydroindole and Tetrahydroindazole Derivatives
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
FR2916443B1 (en) 2007-05-24 2012-08-03 Sanofi Aventis NOVEL ANALOGUE DERIVATIVES OF HERBIMYCIN A, COMPOSITIONS CONTAINING SAME AND USE THEREOF.
DE102007028521A1 (en) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
WO2009007399A1 (en) 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
DE102007032739A1 (en) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate

Also Published As

Publication number Publication date
WO2011004132A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
ECSP10010473A (en) NEW DERIVATIVES OF CARBAZOL, INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE
AR075874A1 (en) INDAZOL DERIVATIVES HSP90 INHIBITORS COMPOSITIONS CONTAINING AND USING
CO6290658A2 (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JACK INHIBITORS
AR119698A2 (en) AMIDE COMPOUND N-UREA SUBSTITUTED AMINO ACID DERIVED
AR085960A1 (en) 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2
AR076435A1 (en) COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES
AR074021A1 (en) FUSIONED HETEROCICLICAL COMPOUNDS AS IONIC CHANNEL MODULATORS
AR090488A1 (en) DERIVATIVES OF N-CYCLLOBUTILBENZAMIDE, A PROCESS FOR OBTAINING, INTERMEDIARIES FOR SYNTHESIS, PESTICIDES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND METHODS FOR CONTROLLING DAMAGES DUE TO A PEST AND / OR FUNDS
AR050941A1 (en) SERINAMIDES REPLACED BY BENZOIL, PROCESSES FOR THEIR PREPARATION, INTERMEDIARIES FOR SYNTHESIS, USE OF THE SAME IN THE MANUFACTURE OF PHYTOSANITARY PRODUCTS AND PROCEDURES TO CONTROL THE GROWTH OF INDENATED PLANTS
CO6210698A2 (en) CHEMICAL COMPOUNDS 637: PYRIDOPIRIMIDINDIONAS AS PDE4 INHIBITORS
AR096979A1 (en) DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR074966A1 (en) AMINO-HETEROCICLIC COMPOUNDS
AR083903A1 (en) DERIVATIVES OF BENZOOXAZOL AND BENZOTIAZOL SULFONAMIDS, USEFUL TO TREAT CARDIAC RHYTHM DISORDERS AND CANCER, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND METHOD TO PREPARE THEM
PE20150224A1 (en) NAMPT INHIBITORS
AR087915A1 (en) N- (3- (2-AMINO-6,6-DIFLUOR-4,4A, 5,6,7,7A-HEXAHYDRO-CYCLOPENTA- [E] [1,3] OXAZIN-4-IL) -PENYL) - AMIDAS AS INHIBITORS OF THE BACE1
AR072510A1 (en) DERIVATIVES OF TRIAZINES AND URACILOS, ITS PREPARATION AND ITS APPLICATION IN HUMAN THERAPEUTICS
AR085088A1 (en) INHIBITORS OF HISTONA DEACETILASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR077080A1 (en) COMPOUNDS OF 2,3-DIHIDRO-1H-INDENO
AR072820A1 (en) DERIVATIVES OF IMIDAZO [1,2-A] PYRIMIDINE, PREPARATION PROCEDURE, INTERMEDIARIES OF SUCH PROCESS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USE THE SAME, AS INHIBITORS OF THE MET PROTEINQUINASE, FOR THE TREATMENT OF CANCERESISES, PSORISISTES, PSORESIST, PSORISIST CENTRAL NERVOUS AND OTHER
AR086036A1 (en) ETHYLLY DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF (mGluR5)
CL2012000003A1 (en) Compounds derived from substituted (6-oxo-1,6-dihydro-pyrimidin-2-yl) -amide; preparation procedure; pharmaceutical composition comprising them; intermediate compounds; and use of said compounds as akt (pkb) phosphorylation inhibitors for the treatment of cancer.
CR20130476A (en) DERIVATIVES OF PIRAZOLIDIN-3-ONA
BR112013016637A2 (en) process for the preparation of 3-alkylsulfinylbenzoyl derivatives
AR075251A1 (en) DERIVATIVES OF 6- (6-REPLACED-TRIAZOLOPIRIDAZINA-SULFANIL) -5-FLUORO-BENZOTIAZOLES AND 5-FLUORO-BENCIMIDAZOLS, METHOD OF PREPARATION AND INTERMEDIARIES OF SYNTHESIS, PHARMACEUTICAL COMPOSITIONS FOR THE CONTAINMENT AND USE OF THE CANTATION AND USE OTHER HYPERPROLIFERATIVE DISORDERS.
ES2561674T3 (en) TRPV4 antagonists

Legal Events

Date Code Title Description
FB Suspension of granting procedure